RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population

Gene

Volumn 498, Issue 2, 2012, Pages 264-269

  Bayram, Süleyman ^a  

^a ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Case control study; Genetic susceptibility; Hepatocellular carcinoma; RASSF1A Ala133Ser polymorphism

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

AGED; ALANINE; AMINO ACID SUBSTITUTION; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SERINE; TUMOR SUPPRESSOR PROTEINS; TURKEY;

EID: 84858752860     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.02.040     Document Type: Article

References (29)

1. Akkiz H., Bayram S., Bekar A., Akgöllü E., Usküdar O., Sandikçi M. No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinoma development in Turkish population: a case-control study. Gene 2011, 486:104-109.
2. Bayram S., Akkiz H., Bekar A., Akgöllü E. The association between the survivin-31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011, 35:555-559.
3. Bergqvist J., et al. RASSF1A polymorphism in familial breast cancer. Fam. Cancer 2010, 9:263-265.
4. Bruix J., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J. Hepatol. 2001, 35:421-430.
5. Donninger H., Vos M.D., Clark G.J. The RASSF1A tumor suppressor. J. Cell Sci. 2007, 120:3163-3172.
6. El-Kalla M., Onyskiw C., Baksh S. Functional importance of RASSF1A microtubule localization and polymorphisms. Oncogene 2010, 29:5729-5740.
7. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
8. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
9. Gao B., et al. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008, 68:22-25.
10. Gordon M., Baksh S. RASSF1A: not a prototypical Ras effector. Small Gtpases 2011, 2:148-157.
11. Hamilton G., Yee K.S., Scrace S., O'Neill E. ATM regulates a RASSF1A-dependent DNA damage response. Curr. Biol. 2009, 19:2020-2025.
12. Hu L., Chen G., Yu H., Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol. Int. 2010, 4:423-432.
13. Jemal A., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
14. Kanzaki H., et al. Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. Cancer Lett. 2006, 238:128-134.
15. Kastan M.B., Lim D.S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 2000, 1:179-186.
16. Liu L., Tommasi S., Lee D.H., Dammann R., Pfeifer G.P. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003, 22:8125-8136.
17. Lodato F., Mazzella G., Festi D., Azzaroli F., Colecchia A., Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J. Gastroenterol. 2006, 12:7239-7249.
18. Lovet J.M., Fuster J., Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004, 10:S115-S120.
19. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the esophagus for bleeding esophageal varices. Br. J. Surg. 1973, 60:646-649.
20. Richter A.M., Pfeifer G.P., Dammann R.H. The RASSF proteins in cancer; from epigenetic silencing to ra-al characterization. Biochim. Biophys. Acta 2009, 1796:114-128.
21. Schagdarsurengin U., et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003, 22:1866-1871.
22. Schagdarsurengin U., Seidel C., Ulbrich E.J., Kölbl H., Dittmer J., Dammann R. A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast. Int. J. Oncol. 2005, 27:185-191.
23. Shivakumar L., Minna J., Sakamaki T., Pestell R., White M.A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol. 2002, 22:4309-4318.
24. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 2010, 108:73-112.
25. Song M.S., et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat. Cell Biol. 2004, 6:129-137.
26. Tsai J.F., Chang W.Y., Jeng J.E., Ho M.S., Lin Z.Y., Tsai J.H. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 1994, 14:98-102.
27. van der Weyden L., Adams D.J. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim. Biophys. Acta 2007, 1776:58-85.
28. Wassmann K., Benezra R. Mitotic checkpoints: from yeast to cancer. Curr. Opin. Genet. Dev. 2001, 11:83-90.
29. Yu M.W., Chen C.J. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res. 1993, 53:790-794.